Abstract
β-Cell failure in type 2 diabetes (T2D) was recently proposed to involve dedifferentiation of β-Cells and ectopic expression of other islet hormones, including somatostatin and glucagon. Here we show that gastrin, a stomach hormone typically expressed in the pancreas only during embryogenesis, is expressed in islets of diabetic rodents and humans with T2D. Although gastrin in mice is expressed in insulin+ cells, gastrin expression in humans with T2D occurs in both insulin+ and somatostatin+ cells. Genetic lineage tracing in mice indicates that gastrin expression is turned on in a subset of differentiated β-Cells after exposure to severe hyperglycemia. Gastrin expression in adult β-Cells does not involve the endocrine progenitor cell regulator neurogenin3 but requires membrane depolarization, calcium influx, and calcineurin signaling. In vivo and in vitro experiments show that gastrin expression is rapidly eliminated upon exposure of β-Cells to normal glucose levels. These results reveal the fetal hormone gastrin as a novel marker for reversible human β-Cell reprogramming in diabetes.
Original language | English |
---|---|
Pages (from-to) | 426-436 |
Number of pages | 11 |
Journal | Diabetes |
Volume | 66 |
Issue number | 2 |
DOIs | |
State | Published - 1 Feb 2017 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2017 by the American Diabetes Association.
Funding
O.Z. was supported by a New York Stem Cell Foundation Druckenmiller Fellowship. This study was supported by grants from JDRF, the Beta Cell Biology Consortium and the Human Islet Research Network of the National Institute of Diabetes and Digestive and Kidney Diseases (DK-104216 and DK-104119), The Leona M. and Harry B. Helmsley Charitable Trust, the European Research Council (BetaToBeta ERC consolidator grant), Britain Israel Research and Academic Exchange Partnership Regenerative Medicine Initiative (14BX14NHBG), the DON Foundation, the Israel Science Foundation, The Soyka Pancreatic Cancer Fund, and Israeli Centers for Research Excellence Program of The Israel Science Foundation #41.11 (to Y.D.).
Funders | Funder number |
---|---|
BetaToBeta ERC | |
Britain Israel Research and Academic Exchange Partnership Regenerative Medicine Initiative | 14BX14NHBG |
Israeli Centers for Research Excellence Program of The Israel Science Foundation | 41.11 |
Soyka Pancreatic Cancer Fund | |
National Institute of Diabetes and Digestive and Kidney Diseases | DK-104216, UC4DK104119 |
New York Stem Cell Foundation | |
Leona M. and Harry B. Helmsley Charitable Trust | |
Juvenile Diabetes Research Foundation United States of America | |
Israel Science Foundation | |
Stichting Diabetes Onderzoek Nederland |